UNSPSC 51112504: Bofumustine

This classification denotes a nitrogen mustard compound with the molecular formula C18H21ClN4O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6P52D0J76B, chemically known as 1-(2-chloroethyl)-3-(2,3-o-isopropylidene-d-ribofuranosyl)-1-nitrosourea 5-(p-nitrobenzoate) but more generally known as bofumustine, which bears US NIH Compound Identifier 100269. European Medicines Agency schedules Bofumustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05865MIG.

UNSPSC 51112504 Bofumustine is a Commodity code identifying a specific pharmaceutical active pharmaceutical ingredient used in cancer chemotherapy. State and local governments procure bofumustine primarily through pharmacy benefit management programs and health plan formularies rather than as direct line-item purchases. The Texas Health and Human Services Commission's April 2026 Request for Information regarding direct-to-manufacturer prescription programs indicates that state health agencies are exploring alternative procurement pathways for specialty pharmaceuticals, moving away from traditional pharmacy benefit manager and group purchasing organization intermediaries toward negotiated net pricing models and outcomes-based agreements with manufacturers. The scope of procurement under this code spans acquisition of the drug itself for use in state employee health plans, Medicaid programs, and correctional or public health facilities, with increasing emphasis on value-based contracting and cost management strategies.

The single recent opportunity comes from Texas HHS, posting a Request for Information in April 2026 to assess vendor and manufacturer capabilities for implementing direct pharmaceutical contracting outside conventional PBM and GPO channels. The RFI sought information from potential vendors regarding their experience with direct contracting for self-insured employers and government health plans, flexibility with negotiated net pricing models, and capacity for outcomes-based agreements. Geographic activity under the code appears limited to Texas at present based on available records; no other states show recent bofumustine-specific procurement activity. The exploratory nature of the Texas RFI suggests the state intends to develop formal procurement specifications and pricing models in subsequent solicitations, making the code potentially more active in the coming months as state health programs formalize specialty pharmaceutical sourcing strategies.